Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice

　　1.Overall Safety and Risk Overview

　　Durvalumab(Brand name:Imfinzi),a PD-L1 inhibitor,exhibits a manageable overall safety profile,with severe adverse events(Grade 3+)occurring in approximately 20-30%of patients,consistent with the class of immune checkpoint inhibitors.The primary clinical challenge stems from Immune-Related Adverse Events(irAEs)caused by immune system overactivation.While most side effects are mild to moderate,vigilance is required for rare but life-threatening events.

　　2.High-Risk irAEs:Identification and Emergency Response

　　Clinicians must prioritize the early detection of high-risk toxicities:

　　Immune-Mediated Pneumonitis(High Risk):​Occurring in about 3-5%of cases,this can be fatal(<0.5%mortality).Symptoms include new cough,dyspnea,or fever.Management ranges from holding therapy and oral steroids for mild cases to permanent discontinuation and IV methylprednisolone for severe cases.

　　Myocarditis&Neurological Toxicity(Critical Risk):​Though rare,immune-mediated myocarditis(with elevated cardiac enzymes)and neurotoxicity(e.g.,Guillain-Barrésyndrome)carry a high mortality rate(~50%).Immediate permanent discontinuation and aggressive intervention are mandatory.

　　3.Management Across Organ Systems

　　System-specific management protocols are essential:

　　Hepatotoxicity:​Monitor liver enzymes monthly.Management is graded by ALT/AST elevation:observe,hold therapy,or permanently discontinue with steroid administration.

　　Colitis:​Presenting as diarrhea or hematochezia(approx.5%incidence).Budesonide or loperamide may suffice for mild cases,while severe colitis requires systemic steroids or permanent discontinuation if perforation occurs.

　　Endocrinopathies:​Hypothyroidism or hyperthyroidism are common but low risk.Hypothyroidism usually requires only hormone replacement without stopping the drug.

　　Skin Reactions&Infusion-Related Reactions:​Generally low risk,managed with topical steroids,antihistamines,or infusion rate adjustments.

　　4.Contraindications and Monitoring Guidelines

　　Durvalumab is generally contraindicated in patients with pre-existing autoimmune diseases(e.g.,SLE,rheumatoid arthritis)or organ transplants due to the risk of exacerbation or rejection.Active infections must be controlled prior to initiation.

　　Baseline screening(blood counts,LFTs,thyroid function,infection markers,chest CT)is required.During treatment,monitor labs every 4-8 weeks.Patient education is crucial:any persistent cough,diarrhea,rash,or palpitations should be reported immediately.